Breztri can cost $400 or more without insurance, but Medicare may cover inhaler drugs for COPD, including Breztri. That said, the specific coverage and costs vary based on your exact plan. Breztri ...
WILMINGTON, Del.--(BUSINESS WIRE)--Positive high-level results from the Phase III KALOS and LOGOS trials in patients with uncontrolled asthma showed that AstraZeneca ...
AstraZeneca’s fixed-dose triple-combination therapy BREZTRI Aerosphere® (budesonide/glycopyrrolate/formoterol fumarate or BGF 320/36/9.6μg) has been approved in ...
With data from a second phase 3 trial, AstraZeneca has finally convinced FDA regulators that its new COPD offering deserves a place on the U.S. market just as a competitor from GlaxoSmithKline does.
Positive and clinically meaningful results from the Phase III KALOS and LOGOS trials for BREZTRIin patients with uncontrolled asthma published in The Lancet Respiratory Medicine Full results from the ...
The US Food and Drug Administration (FDA) Office of Prescription Drug Promotion (OPDP) has sent a warning letter to AstraZeneca, taking the drugmaker to task over misleading promotional material for ...
THARROS is the first-ever prospective trial to investigate the potential of an inhaled triple therapy to reduce cardiopulmonary events, a key driver of mortality, in COPD First patients dosed in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results